177 Vipivotide Tetraxetan

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!

Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!

Journal: Nuklearmedizin. Nuclear medicine

Published: November 26, 2025

Differential Clearance of [177Lu]Lu-PSMA-617 from Metastatic Prostate Cancer Lesions and Normal Tissues creates a Window for Safe Application of DNA Repair Inhibitors.

Differential Clearance of [177Lu]Lu-PSMA-617 from Metastatic Prostate Cancer Lesions and Normal Tissues creates a Window for Safe Application of DNA Repair Inhibitors.

Journal: medRxiv : the preprint server for health sciences

Published: November 24, 2025

FDA expanded approval of Pluvicto (Lutetium-177 vipivotide tetraxetan) in metastatic castration-sensitive prostate cancer.

FDA expanded approval of Pluvicto (Lutetium-177 vipivotide tetraxetan) in metastatic castration-sensitive prostate cancer.

Journal: Annals of medicine and surgery (2012)

Published: November 19, 2025

Global Challenges in the Provision of Theranostic Services the International Atomic Energy Agency (IAEA) Perspective.

Global Challenges in the Provision of Theranostic Services the International Atomic Energy Agency (IAEA) Perspective.

Journal: World journal of nuclear medicine

Published: November 12, 2025

Lutetium Lu 177 vipivotide tetraxetan: A literature review.

Lutetium Lu 177 vipivotide tetraxetan: A literature review.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: November 11, 2025

How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated.

How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated.

Journal: Journal of medicinal chemistry

Published: October 06, 2025

Radioligand Therapy in Cancer Management: A Global Perspective.

Radioligand Therapy in Cancer Management: A Global Perspective.

Journal: Cancers

Published: September 23, 2025

Understanding the Factors Related to Early Discontinuation of Lutetium-177 Vipivotide Treatment in Men With Metastatic Castration-Resistant Prostate Cancer at a Single Institution.

Understanding the Factors Related to Early Discontinuation of Lutetium-177 Vipivotide Treatment in Men With Metastatic Castration-Resistant Prostate Cancer at a Single Institution.

Journal: Cureus

Published: September 08, 2025

Prostate-Specific Membrane Antigen Positron Emission Tomography-Detected Intrahepatic Cholangiocarcinoma in a Patient With Metastatic Castration-Resistant Prostate Cancer: Dual Cancer Management With Pluvicto and Intensity-Modulated Radiation Therapy.

Prostate-Specific Membrane Antigen Positron Emission Tomography-Detected Intrahepatic Cholangiocarcinoma in a Patient With Metastatic Castration-Resistant Prostate Cancer: Dual Cancer Management With Pluvicto and Intensity-Modulated Radiation Therapy.

Journal: Cureus

Published: August 15, 2025

Lutetium 177Lu Vipivotide Tetraxetan Efficacy and Toxicity in Advanced Prostate Cancer.

Lutetium 177Lu Vipivotide Tetraxetan Efficacy and Toxicity in Advanced Prostate Cancer.

Journal: Advances in radiation oncology

Published: July 10, 2025

Radionuclides Landscape in Prostate Cancer Theranostics.

Radionuclides Landscape in Prostate Cancer Theranostics.

Journal: International journal of molecular sciences

Published: June 17, 2025

Optimizing PSMA-617-based inhibitors through charged linker modifications: Insights into structure-activity relationships.

Optimizing PSMA-617-based inhibitors through charged linker modifications: Insights into structure-activity relationships.

Journal: Theranostics

Published: June 05, 2025

Showing 1-12 of 61

Last Updated: 02/24/2026